Mr. Bill Ciprick reports

OPTIMI HEALTH TO SUPPLY MDMA FOR THERAPIST EXPERIENTIAL TRAINING PROGRAM AT NUMINUS, SUPPORTED BY MAPS

Optimi Health Corp. has been selected to manufacture and supply MDMA for a practitioner experiential clinical trial, sponsored by Numinus Wellness Inc., announced earlier today. This clinical trial will provide practitioners training to provide MDMA-assisted therapy with the opportunity to participate in experiential training -- through a training partnership between Numinus and the Multidisciplinary Association for Psychedelic Studies (MAPS).

The clinical trial application has been submitted by Numinus through its wholly owned subsidiary, Numinus Wellness Research Inc. If approved by Health Canada, the clinical trial would enable practitioners interested in MDMA-assisted therapy the ability to experience and observe MDMA sessions to further their understanding of psychedelic-assisted therapy and allow Numinus to test the safety and efficacy of MDMA in healthy subjects.

Optimi chief executive officer Bill Ciprick says this latest supply partnership confirms the company's all-in approach to supporting therapists and being a preferred supplier of MDMA.

"Optimi is committed to supporting Numinus and MAPS as they prepare to meet this immediate need for therapist and practitioner training," said Mr. Ciprick. "Therapists provided experiential training within the parameters of this partnership will be able to provide a greater standard of care to patients undergoing these treatments. We are excited to be part of the journey."

Numinus founder and chief executive officer Payton Nyquvest added: "We are thrilled to announce this unique partnership with Optimi that opens the doors to a groundbreaking opportunity for psychedelic therapists worldwide. Along with MAPS, we are pioneering a new era of research and access to MDMA-assisted therapy, empowering therapists to unlock transformative healing journeys for their clients. This collaboration represents our unwavering commitment to expanding the frontiers of mental health, providing a safe and guided path towards profound healing and personal growth."

Optimi will answer questions during a live webinar after the MAPS Psychedelic Science 2023 conference. Details to follow.

About Optimi Health Corp.

Optimi Health is an end-to-end Canadian-based drug researcher and formulator licensed by Health Canada to produce and supply psychedelic substances such as MDMA" and natural, GMP-grade (good manufacturing practice) psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the company's goal is to be the No. 1 trusted, compassionate supplier of safe drug products throughout the world.

We seek Safe Harbor.